Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the presence
of antiphospholipid antibodies (aPL)(lupus anticoagulant, anticardiolipin antibodies and anti …

Rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), the two most common
systemic autoimmune disorders, have both unique and overlapping manifestations. One …

HIV infection has been recognized as a prothrombotic condition and this association has
now been proven by a large number of studies with a reported VTE frequency among HIV …

Nitric oxide (NO) is a powerful biological mediator provided with a number of activities of
relevance for the prevention of thrombosis, like vasodilation, inhibition of platelet adhesion …

Objective To describe the baseline characteristics of patients with positivity for
antiphospholipid antibodies (aPLs) who were enrolled in an international registry, the …

CVD is a major complication of lupus and is now a leading cause of death among people
living with this disease. As such, additional studies are needed in order to identify the most …

Objectives Patients with antiphospholipid syndrome (APS) are at risk for subclinical
endothelial injury, as well as accelerated atherosclerosis. In the related disease systemic …

Patients with systemic lupus erythematosus (SLE) have an increased risk of developing
cardiovascular disease (CVD). Traditional risk factors fail to fully explain all of this increased …

The association between venous thromboembolism and arterial thrombosis has emerged as
consistent clinical observation in the last few years. While several experimental …

BACKGROUND: There is strong evidence that antiphospholipid antibodies (aPL) perturb
endothelium both in vitro and in experimental animal models. by inducing a vasculopathy …